This research used linked electronic health record and claims data of OAB patients which were provided for a fee from Humedica. The minimal data set required to replicate our findings is available for purchase by any researcher from <https://www.optum.com/solutions/data-analytics/data/real-world-data-analytics-a-cpl/claims-data.html>.

Introduction {#sec001}
============

Overactive bladder (OAB) is characterized by urge urinary incontinence and urgency, nocturia, and high urinary frequency. The prevalence of OAB has been estimated to be 11.8% in the United States (US), with higher rates in older individuals.\[[@pone.0205640.ref001]\] While behavioral modifications including bladder training, pelvic floor training, and limitation of fluids are intended as the first line of treatment for OAB, pharmacologic intervention is a mainstay of OAB management.\[[@pone.0205640.ref002]\] To date, antimuscarinic therapies--including oxybutynin, tolterodine, solifenacin, flavoxate, fesoterodine, trospium, or darifenacin--have been the most common first-line pharmacologic treatment for OAB.\[[@pone.0205640.ref003]\] Mirabegron (Myrbetriq/Betmiga; Astellas Pharma) is a β3 adrenergic receptor agonist with demonstrated efficacy and safety in managing the symptoms of OAB.\[[@pone.0205640.ref004]\] In clinical practice, mirabegron is typically given as second-line pharmacotherapy after discontinuation or failure of therapy with antimuscarinics.\[[@pone.0205640.ref003]\] While clinical trials have shown mirabegron to be both efficacious and safe,\[[@pone.0205640.ref004]\] in two randomized, placebo-controlled studies of healthy volunteers, mirabegron was associated with dose-related increases in supine blood pressure with the currently marketed and maximum recommended dose of 50 mg.\[[@pone.0205640.ref005]\] The mean increase in systolic blood pressure (SBP)/diastolic blood pressure (DBP) was approximately 3.5/1.5 mm Hg greater than placebo. In three, phase 3, 12-week, double-blind, placebo-controlled, safety and efficacy studies of OAB patients receiving mirabegron 25 mg, 50 mg or 100 mg once daily, mean increases in SBP/DBP of approximately 0.5--1.0 mm Hg were observed compared to placebo.\[[@pone.0205640.ref005]\] Both SBP and DBP increases were reversible upon discontinuation of treatment.\[[@pone.0205640.ref005]\]

It is important to determine whether findings from randomized controlled studies are also observed in a real-world setting. In a real-world setting, integrated electronic health record (EHR) and claims data can also provide confirmation of dispensed--as opposed to prescribed--medications, as well as details of baseline cardiovascular risk profiles (e.g. vital signs, smoking status) that are not typically captured in billing claims but are required to inform any necessary statistical adjustments. To date, a real-world assessment of cardiovascular risk in OAB patients has not been conducted.

A key challenge in this setting is the potential for residual bias in observational data due to unmeasured confounders and/or confounding by indication, e.g. if patients receiving any OAB treatment are systematically different from patients receiving alternative therapies, or those who are untreated. Addressing residual bias is critical when using observational data to probe comparative outcomes.\[[@pone.0205640.ref006]\] In previous database analyses it was found that OAB patients initiating mirabegron tended to be older at treatment initiation, with a greater comorbidity burden and higher healthcare resource utilization, compared to those initiating treatment with antimuscarinics.\[[@pone.0205640.ref003]\] This is likely a result of mirabegron's typical positioning as a second-line pharmacological agent after failure of antimuscarinics.\[[@pone.0205640.ref003]\]

The overarching aim of the study was, using the most appropriate statistical methodology for mitigating residual bias, to compare baseline cardiovascular risk profiles of OAB patients initiating antimuscarinics vs. mirabegron, and determine comparative cardiovascular outcomes, such as blood pressure change, between treatment groups. However, prior to undertaking that investigation, the team planned an unbiased a priori assessment of the feasibility of that comparative study, with a particular focus on determining whether potential residual bias could be present due to unmeasured confounding, including differences in prior treatment patterns and treatment switching. Should the initial feasibility assessment satisfy the study team that a rigorous study could be conducted, a larger outcome comparative analysis would then be undertaken. The objective of the study described here is to compare cardiovascular risk profiles of OAB patients initiating antimuscarinics vs. mirabegron; and to present the findings of the feasibility assessment for the comparative study of cardiovascular outcomes across treatment groups that the cardiovascular risk profiles informed.

Methods {#sec002}
=======

Study design and patient population {#sec003}
-----------------------------------

The study was designed as a real-world, US-based retrospective cohort study of patients receiving treatment for OAB. Data were available from October 2011 to June 2015.

The overall study population was derived from all individuals diagnosed with OAB, based on the International Classification of Diseases-9^th^ Edition (ICD-9) codes that indicate a diagnosis of OAB (ICD-9 596.65,596.51,788.3,788.31,788.33,788.41,788.43,788.63,788.91). While there is no specific ICD-9 code for OAB, the proposed ICD-9 codes above are consistent with previously published research that evaluated OAB patients using real-world datasets.\[[@pone.0205640.ref007]--[@pone.0205640.ref010]\]

For the feasibility assessment, patients were eligible for inclusion based on dispensation billing records for mirabegron or an antimuscarinic therapy (oxybutynin, solifenacin, tolterodine, flavoxate, fesoterodine, trospium, darifenacin) between October 2012 and December 2014 ("identification period"). Both EHR records of prescriptions written and billing claims for dispensed prescriptions were initially considered for patient identification, however due to a large discrepancy indicating a high frequency of unfilled prescriptions (more than twice as many prescriptions were identified in the EHR versus the claims data), claims billing records were ultimately used to determine eligibility. Index date was defined as first prescription dispensation during the identification period. Patients with a diagnosis for OAB without a billing record for mirabegron or an antimuscarinic were included in the untreated cohort as of their first OAB-related health claim during the identification period. Data from October 2011 onwards were used to characterize medical and treatment history for each patient in the 12 months prior to index date. Follow-up included time from index date through June 2015 with a minimum potential follow-up of six months for those patients having an index date in December 2014. Follow-up times were censored for those individuals who died or left the claims database due to changing coverage. Patients were included in the mirabegron or antimuscarinic treatment group based on the first treatment they received during the identification period, noting that treatment switching after index date may have occurred, and that patients may have received other OAB therapies prior to the identification period.

Further eligibility criteria required that patients:

-   Had at least 12 months of continuous coverage in the claims data prior to index date in order to comprehensively assess risk factors and comorbidities at baseline;

-   Were 18 years of age or older and have at least one baseline blood pressure (measured and reported using methodologies per usual clinical practice) recorded in the EHR within 90 days prior to index date.

The criteria for exclusion were:

-   Pregnancy during the study period;

-   Received combination therapy of mirabegron and an antimuscarinic at index date;

-   Received pharmacologic therapy for OAB during the year prior to the identification period but remained untreated for OAB during the identification period;

-   Had a recorded cardiovascular event (myocardial infarction, unstable angina, cardiovascular death, cerebrovascular accident, peripheral arteriopathy, aortic event, heart failure, coronary artery bypass grafting, atrial fibrillation, transient ischemic attack, percutaneous intervention, angioplasty)\[[@pone.0205640.ref011]\] within 30 days prior to the index date.

If the feasibility assessment indicated it reasonable to proceed with the cardiovascular outcomes study, the goal of those analyses would be to determine whether differences in SBP and/or DBP changes occur in patients receiving mirabegron compared to antimuscarinics, and the association of those changes with cardiovascular events. It was therefore also important to perform sample size calculations *a priori*, to determine whether the available number of patients meeting the inclusion and exclusion criteria would be sufficient, if the outcome of the feasibility assessment to identify residual bias justified proceeding with the cardiovascular outcomes study. Details of the calculations are included in Appendix A. At power of 0.80, a sample of 500 mirabegron patients and 1500 antimuscarinic patients would be required to detect a systolic blood pressure difference of 2.5 mmHg assuming a 14 mmHg standard deviation. When based on a power of 0.90, the sample size increased to 645 mirabegron patients and 1935 antimuscarinic patients.

All analyses were conducted in SAS version 9.4.

Data source {#sec004}
-----------

The study utilized an Optum integrated claims billing and EHR dataset from the US. The Optum claims dataset is widely used for pharmacoepidemiologic, pharmacoeconomic, and outcomes research studies in a variety of diseases,\[[@pone.0205640.ref012], [@pone.0205640.ref013]\] including cardiovascular diseases \[[@pone.0205640.ref014]\] and OAB.\[[@pone.0205640.ref015]\] The Optum dataset includes the eligibility, medical, and pharmacy claims data from United Health, a large commercial health plan affiliated with Optum. The individuals included within this health plan are geographically diverse, from across the US, comprising approximately 3 to 4% of the US population. The database includes data from 2003 to 2015 and has almost 13 million registrants annually.

Optum claims data were integrated with Humedica primary care EHR data for the subset of the Optum OAB population included in both datasets. Inclusion in the Humedica EHR is based on physician participation in the network. Reported EHR data include medications, laboratory results, vital signs, demographics, hospitalizations, outpatient visits, and physician notes. Claims data linked to the EHR can be used to identify those prescriptions that were actually dispensed, indicating that identified patients filled a prescription for the study medication. Hence medication use in this study was defined by claims rather than EHR data. By linking the Humedica EHR data to Optum claims data, it is possible to identify prescriptions filled by patients, along with cost and charge amounts associated with all covered healthcare utilization.

Bias reduction {#sec005}
--------------

Initial unadjusted comparisons conducted for the feasibility assessment were descriptive in nature and statistical comparisons were not made across treatment groups. A propensity score analysis was undertaken to mitigate the effects of bias within the observational data source. A logistic regression model was fit to characterize the likelihood (i.e., propensity score) of an individual being in the mirabegron treatment group, while adjusting for a range of demographic (age, sex, ethnicity, health plan type, geographic region variables) and clinical (smoking status, BMI, blood pressure, cholesterol, cardiovascular history, comorbidities, concomitant medications) variables. It was anticipated *a priori* that there would be substantially more antimuscarinic patients than mirabegron patients available in the dataset and that an n:1 matching algorithm would make most efficient use of the available data. Based on exploratory review of the eligible population sizes, antimuscarinic patients were propensity score matched to mirabegron patients in a 3:1 manner using a greedy matching algorithm to form the analytic sample.\[[@pone.0205640.ref016]\]

Quality assessment and falsification analysis {#sec006}
---------------------------------------------

An assessment of data quality and completeness was required prior to undertaking further analyses. Due to the nature of US health insurance, OAB patients can enter and leave the enrollment plan over time, whereby a hiatus in coverage could be observed in either one or both data sources. Quality assessment of the data focused on a test sample of individuals untreated for OAB and included: comparison of all blood pressure, cholesterol, age, and BMI against plausible ranges (overall and stratified by age \<65 vs. ≥ 65 and sex); and rates of missing values in variables included in the propensity score model. Within the treated cohorts, additional quality checks included tabulation of censoring from the cohort and reasons for drop out; assessment of overlap and gaps across EHR and claims data; and assessment of treatment switches across antimuscarinics and mirabegron following index date, which enabled characterization of the proportion of follow-up time that a mirabegron patient was exposed to antimuscarinics and vice-versa.

While numerous analytic methods are available to address confounding by indication, adequately minimizing bias may not be feasible, particularly in the case of unmeasured confounders.\[[@pone.0205640.ref017]--[@pone.0205640.ref019]\] Falsification analysis is a method that has recently been proposed for assessing the potential for residual bias in analyzing a specific research question in an observational data source.\[[@pone.0205640.ref020], [@pone.0205640.ref021]\] Within a falsification analysis, an endpoint thought to be unrelated to the exposure of interest is pre-specified, and the association between this outcome and the exposure is tested after statistical adjustments have been made. Any spurious residual association observed between the exposure and the falsification outcome suggests that bias may be present within the data, and additional analyses are not recommended unless this bias can be explicitly addressed.

Falsification endpoints with no known association with either medication class under study were pre-specified by clinical experts, and included shingles (ICD-9 053\[[@pone.0205640.ref022]\]), hepatitis C virus (ICD-9 070.44\[[@pone.0205640.ref023]\]), and community-acquired pneumonia (ICD-9 480.x-486.x\[[@pone.0205640.ref024]\]). For each falsification endpoint, odds ratios and corresponding 95% confidence intervals (CIs) of the association between treatment and outcome were calculated for the mirabegron and antimuscarinic propensity-matched cohorts.

Results {#sec007}
=======

To derive the study sample, 34,243 individuals (1,417 ever treated with mirabegron and 32,836 ever treated with an antimuscarinic) were initially identified for potential inclusion ([Fig 1](#pone.0205640.g001){ref-type="fig"}), based on a diagnosis of OAB and a billing record for a dispensed prescription at any point in time (e.g. not necessarily during the study period). It is of interest to note that more than twice as many patients had a record of a written prescription for mirabegron or an antimuscarinic in the EHR (data not shown) without a record of a prescription being dispensed in the claims data, perhaps indicating concerns with primary adherence and potential for bias in inducing differences across treatment groups. More than half of antimuscarinic patients (n = 17,426) and approximately one third of mirabegron patients (n = 847) were excluded because they were not dispensed a prescription during the study follow-up period (i.e. while these individuals received the medication of interest at some point during data coverage, they did not have a filled prescription during the study period). Of the resulting 15,980 patients (15,410 who received an antimuscarinic during the study period and 570 receiving mirabegron), most had 12 months' continuous data available prior to the index date in at least one of the EHR or claims databases, and were at least 18 years of age, with only a small number of exclusions related to these criteria (n = 16 exclusions for mirabegron and n = 740 exclusions for antimuscarinics). The requirement of a blood pressure measure being available within 90 days of index date resulted in 137 exclusions in the mirabegron arm and 4,163 exclusions in the antimuscarinic arm. A small number of exclusions were made due to recent pregnancy and/or cardiovascular events. After applying all inclusion and exclusion criteria, the final sample was reduced to 408 mirabegron patients and 10,311 antimuscarinic patients. The antimuscarinic group was then further reduced to create a 3:1 propensity-matched sample to mirabegron. After 3:1 propensity matching, the final sample size was 396 in the mirabegron group and 1,188 in the antimuscarinic group. Thus, of the 15,980 OAB patients who received a prescription during the study period, approximately ten percent were eligible for the final analytic study population.

![Cohort attrition.](pone.0205640.g001){#pone.0205640.g001}

During the quality assessment stage, baseline blood pressure measurements were available for most individuals in the untreated group (77.7%), with less than 0.5% of these data flagged as implausible or likely data entry errors. Women were more likely to have recorded blood pressure measures available (80.7% vs.73.2%), and there was no noted difference in blood pressure measure availability by age. Within the treated cohorts, both treatment cohorts had more than a year of follow-up on average (555 days for antimuscarinic patients, 456 days for mirabegron patients). A gap in coverage of at least 30 days was noted in 3.6% of antimuscarinic patients and 2.2% of mirabegron patients. Drop-out during the study period occurred in 34.1% of antimuscarinic patients (30.9% leaving plan, 3.2% death) and 21.1% of antimuscarinic patients (19.1% leaving plan, 2.0% death). Four percent of antimuscarinic patients switched treatment to mirabegron after index date, compared to 18.9% of mirabegron patients who had at least one antimuscarinic claim after index date. The result of the quality assessment process was a decision to proceed to the next phase of the study.

Baseline demographic characteristics prior to propensity matching, for both untreated and treated OAB patients, are shown in [Table 1](#pone.0205640.t001){ref-type="table"}. Mirabegron patients tended to be older (mean age 70.1 years vs. 66.7, p\<0.0001), were more likely to be male (33.6% vs. 26.8%, p = 0.01), Caucasian (88.7% vs. 85.9%, p = 0.24), and to be covered by supplementary Medicare (56.1% vs. 34.3%, p = 0.15), relative to antimuscarinic patients. The most notable difference between untreated and treated OAB patients was that the former group tended to be younger, with a mean age of 59.9 years, and 15.3% under age 40 years.

10.1371/journal.pone.0205640.t001

###### Baseline demographic characteristics by OAB treatment group.

![](pone.0205640.t001){#pone.0205640.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                     Any OAB\       Antimuscarinics\   Mirabegron\   Untreated\     p-value\                                                                              
                                                                     (N = 64,906)   (N = 10,311)       (N = 408)     (N = 54,187)   (2 sided)[\*\*\*](#t001fn004){ref-type="table-fn"}                                    
  ------------------------------------------------------------------ -------------- ------------------ ------------- -------------- ---------------------------------------------------- ---------- ---------- ---------- ----------------------------------------------
  Age at index date (years)                                                                                                                                                                                               

      Mean (SD)                                                      61.1           17.0               66.7          13.7           70.1                                                 12.5       59.9       17.3       \<0.001[\*](#t001fn002){ref-type="table-fn"}

      Median (IQR)                                                   64             50--75             69            58--78         73                                                   62--80     62         48--74     

      Category, n(%):                                                                                                                                                                                                     \<0.001[\*](#t001fn002){ref-type="table-fn"}

      18--39                                                         8,372          12.9               427           4.1            11                                                   2.7        7,934      14.6       

      40--59                                                         18,722         28.8               2,459         23.8           61                                                   15.0       16,202     29.9       

      60--79                                                         27,108         41.8               5,142         49.9           221                                                  54.2       21,745     40.1       

      ≥80                                                            10,704         16.5               2,283         22.1           115                                                  28.2       8,306      15.3       

  Sex, n (%)                                                                                                                                                                                                              0.010

      Females                                                        40,522         62.4               7544          73.16          271                                                  66.42      32,731     50.4       

      Males                                                          24,357         37.5               2,764         26.8           137                                                  33.6       21,456     39.6       

      Sex unknown                                                    27             0.0                3             0.0            0                                                    0.0        24         0.0        

  Race, n(%)                                                                                                                                                                                                              0.239

      African American                                               4,903          7.6                800           7.8            22                                                   5.4        4,081      7.5        

      Asian                                                          1,295          2.0                134           1.3            3                                                    0.7        1,158      2.1        

      Caucasian                                                      53,380         82.2               8,862         85.9           362                                                  88.7       44,156     81.5       

      Other/ Unknown                                                 5,328          8.2                515           5.0            21                                                   5.1        4,792      8.8        

  Ethnicity, n(%)                                                                                                                                                                                                         0.111

      Hispanic                                                       2,223          3.4                313           3.0            12                                                   2.9        1,898      3.5        

      Non-Hispanic                                                   55,436         85.4               9,354         90.7           360                                                  88.2       45,722     84.4       

      Unknown                                                        7,247          11.2               644           6.2            36                                                   8.8        6,567      12.1       

  Primary payer, n(%)                                                                                                                                                                                                     0.149

      Commercial                                                     36,471         56.2               5,568         54.0           146                                                  35.8       13,327     24.6       

      Medicaid                                                       863            1.3                203           2.0            5                                                    1.2        655        1.2        

      Medicare                                                       17,008         26.2               3,535         34.3           229                                                  56.1       30,674     56.6       

      Other Payor Type                                               1,236          1.9                176           1.7            4                                                    1.0        1,056      1.9        

      Uninsured                                                      682            1.1                116                                                                                                                

      Unknown                                                        8,646          13.3               713           6.9            24                                                   5.9        7,909      14.6       

  Geographic area, n(%)[\*\*](#t001fn003){ref-type="table-fn"}                                                                                                                                                            \<0.001[\*](#t001fn002){ref-type="table-fn"}

      East North Central                                             17,665         27.2               3,022         29.3           84                                                   20.6       14,559     26.9       

      East South Central                                             1,282          2.0                248           2.4            15                                                   3.7        1,019      1.9        

      Middle Atlantic                                                7,005          10.8               529           5.1            48                                                   11.8       6,428      11.9       

      Mountain                                                       1,433          2.2                196           1.9            2                                                    0.5        1,235      2.3        

      New England                                                    1,693          2.6                284           2.8            4                                                    1.0        1,405      2.6        

      Other/ Unknown                                                 1,622          2.5                209           2.0            4                                                    1.0        1,409      2.6        

      Pacific                                                        4,967          7.7                1,010         9.8            19                                                   4.7        3,938      7.3        

      South Atlantic/West South Central                              19,357         29.8               3,481         33.8           196                                                  48.0       15,680     28.9       

      West North Central                                             9,882          15.2               1,332         12.9           36                                                   8.8        8,514      15.7       

  College education, n(%)[\*](#t001fn002){ref-type="table-fn"}                                                                                                                                                            \<0.001[\*](#t001fn002){ref-type="table-fn"}

      \< 14%                                                         1,172          1.8                185           1.8            3                                                    0.7        984        1.8        

      14 to 18%                                                      11,349         17.5               2,375         23.0           146                                                  35.8       8,828      16.3       

      19 to 28%                                                      29,499         45.4               4,625         44.9           133                                                  32.6       24,741     45.7       

      \>28%                                                          21,257         32.8               2,915         28.3           122                                                  29.9       18,220     33.6       

      Education status unknown, n(%)                                 1,629          2.5                211           2.0            4                                                    1.0        1,414      2.6        

  Household income, mean (SD)[\*](#t001fn002){ref-type="table-fn"}   \$45,645       \$11,838           \$44,198      \$10,776       \$43,228                                             \$11,435   \$45,940   \$12,012   0.093
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N = number; SD = Standard deviation

\* Mirabegron vs. antimuscarinics

\*\*Recorded at the level of the 3-digit zip code

\*\*\* p-value calculated for the antimuscarinics and mirabegron treatment groups

Baseline unmatched clinical characteristics are reported in [Table 2](#pone.0205640.t002){ref-type="table"}. Most distributions were similar across treatment groups. Differences among mirabegron patients include a higher rate of prior major adverse cardiovascular events (13.5% vs 11.7% in antimuscarinic patients and 10.1% in untreated patients in the year prior to baseline, p = 0.2687), and a higher rate of diabetes mellitus (42.4% vs 34.8% in antimuscarinic patients and 26.3% in untreated patients, p = 0.0021).

10.1371/journal.pone.0205640.t002

###### Baseline clinical characteristics by OAB treatment group.

![](pone.0205640.t002){#pone.0205640.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               Any OAB\         Antimuscarinics\   Mirabegron\   Untreated\     p-value\                                                                   
                                                               (N = 64,906)\_   (N = 10,311)       (N = 408)     (N = 54,187)   (2 sided)[\*](#t002fn002){ref-type="table-fn"}                             
  ------------------------------------------------------------ ---------------- ------------------ ------------- -------------- ------------------------------------------------ ------- -------- -------- ----------
  Current smoker, n(%)                                         6,051            9.3                1,158         11.2           40                                               9.8     4,853    9.0      0.209

      Smoking status unknown                                   13,787           21.2               1,179         11.4           29                                               7.1     12,579   23.2     

  BMI, mean (SD)                                               34.88            295.1              33.31         125.9          42.84                                            264.1   35.1     320.7    0.468

  BMI, n(%)                                                                                                                                                                                                

      \<18.5                                                   828              1.3                141           1.4            6                                                1.5     681      1.3      0.001

      18.5--24.9                                               14,998           23.1               2,308         22.4           90                                               22.1    12,600   23.3     

      25.0--29.9                                               18,171           28.0               2,989         29.0           150                                              36.8    15,032   27.7     

      ≥30.0                                                    20,943           32.3               4,367         42.4           155                                              38.0    16,421   30.3     

      Unknown                                                  9,966            15.4               506           4.9            7                                                1.7     9,453    17.4     

  Most recent BP measure                                                                                                                                                                                   

      SBP, mean (SD)                                           126.5            17.6               128.4         17.9           128.9                                            17.4    126.0    17.5     0.570

      DBP, mean (SD)                                           74.4             10.5               73.9          10.5           72.7                                             10.4    74.5     10.4     0.023

      JNC-7 category, n(%)                                                                                                                                                                                 

      SBP\<120 mmHg and DBP\<80 mmHg                           17,010           26.2               2,709         26.3           100                                              24.5    14,201   26.2     0.455

      SBP 120--139 mmHg or DBP 80--89 mmHg                     32,433           50.0               5,922         57.4           230                                              56.4    26,281   48.5     

      SBP 140--159 mmHg or DBP 90--99 mmHg                     6,572            10.1               1,374         13.3           65                                               15.9    5,133    9.5      

      SBP ≥160 mmHg or DBP ≥100 mmHg                           1,081            1.7                254           2.5            11                                               2.7     816      1.5      

  Most recent cholesterol measure, mean (SD)                                                                                                                                                               

      HDL                                                      53.8             16.8               53.8          16.73          53.60                                            17.1    53.86    16.88    0.817

      LDL                                                      104.7            348.4              100.6         33.86          97.12                                            34.5    105.71   389.28   0.046

  HDL unknown, n(%)                                            28,746           44.3               3,326         8.2            153                                              1.5     25,267   46.6     0.939

  LDL unknown, n(%)                                            28,781           44.3               3,317         8.1            155                                              1.5     25,309   46.7     

  Any CV events prior to index date, n(%)                                                                                                                                                                  

      MACE                                                     6,747            10.4               1,208         11.7           55                                               13.5    5,484    10.1     0.269

      non-MACE                                                 4,979            7.7                842           8.2            38                                               9.3     4,099    7.6      0.427

      Any (MACE or non-MACE)                                   8,209            12.6               1,478         14.3           70                                               17.2    6,661    12.3     0.102

  Time since most recent event, mean (SD)                                                                                                                                                                  

      MACE                                                     637.2            631.2              580.2         576.4          647.1                                            684.2   649.6    641.6    0.0517

      non-MACE                                                 600.4            609.5              544.7         555.0          525.5                                            568.7   612.5    619.9    0.503

      Any (MACE or non-MACE)                                   633.8            627.3              573.3         571.0          592.7                                            636.8   647.6    638.3    0.545

  Number of recorded CV events prior to index date, mean(SD)                                                                                                                                               

      MACE                                                     0.6              2.7                0.6           3.0            0.7                                              3.0     0.54     2.7      0.509

      non-MACE                                                 0.4              2.3                0.4           2.4            0.4                                              2.3     0.38     2.3      1.000

      Any (MACE or non-MACE)                                   0.8              3.5                0.9           3.8            1.0                                              3.8     0.77     3.5      0.602

  Other CV comorbidities, n(%)                                                                                                                                                                             

      Chronic kidney disease                                   6,972            10.7               1,593         15.4           59                                               14.5    5,320    9.8      0.621

      Diabetes mellitus                                        17,992           27.7               3,589         34.8           172                                              42.2    14,231   26.3     0.002

  Any prescription at index date, mean (SD)                    1.8              1.5                2.2           1.9            1.6                                              1.5     1.5      1.0      p\<0.001

  History of OAB medication, n(%)                                                                                                                                                                          

      Antimuscarinics                                          4,394            6.8                4,327         42.0           67                                               16.4    0        0.0      \<0.001

      Mirabegron                                               0                0.0                0             0.0            0                                                0.0     0        0.0      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BP = Blood pressure; CV = Cardiovascular; DBP = Diastolic blood pressure; HDL = High-density lipoprotein; LDL = Low-density lipoprotein; MACE = Major adverse cardiac event; N = number; SBP = Systolic blood pressure; SD = Standard deviation

\* p-value calculated for the Antimuscarinics and mirabegron treatment groups

The propensity score model included terms characterizing baseline demographics and clinical events, prior cardiovascular events, and pre-index blood pressure. After 3:1 propensity score matching, 396 of 408 mirabegron patients were matched to a corresponding sample of 1,188 antimuscarinic patients. The distributions of variables of interest before and after matching are reported in [Table 3](#pone.0205640.t003){ref-type="table"}, and standardized differences before and after matching are shown in [Fig 2](#pone.0205640.g002){ref-type="fig"}. Prior to matching a number of variables were statistically different across the two treatment groups. Generally, mirabegron patients were more likely to have comorbidities, while antimuscarinic patients were more likely to be receiving concomitant medications. Propensity score matching was successful at reducing covariate imbalance across the treatment groups. After matching, no variables were statistically different between the two groups and all but one of the post-matching standardized difference was less than 0.10.

![Standardized differences before and after propensity score matching.](pone.0205640.g002){#pone.0205640.g002}

10.1371/journal.pone.0205640.t003

###### Results of propensity score matching on demographic characteristics.

![](pone.0205640.t003){#pone.0205640.t003g}

                                                         Unmatched   3:1 propensity matched                                                      
  ------------------------------------------------------ ----------- ------------------------ ----- ------ --------- ------ ------ ------ ------ -------
  Age group at index date                                                                                                                        
      18--39 yrs                                         427         4.1                      11    2.7    \<0.001   31     2.6    11     2.8    0.874
      40--59 yrs                                         2459        23.9                     61    15.0   188       15.8   61     15.4          
      60--79 yrs                                         5142        49.9                     221   54.2   666       56.1   215    54.3          
      80 or older                                        2283        22.1                     115   28.2   303       25.5   109    27.5          
  Sex                                                                                                                                            
      Female                                             7544        73.2                     271   66.4   0.010     817    68.8   267    67.4   0.618
      Male                                               2764        26.8                     137   33.6   371       31.2   129    32.6          
      Unknown                                            3           0.0                      0     0.0                                          
  Race                                                                                                                                           
      African America                                    800         7.8                      22    5.4    0.239     54     4.6    22     5.6    0.721
      Asian                                              134         1.3                      3     0.7    15        1.3    3      0.8           
      Caucasian                                          8862        86.0                     362   88.7   1056      88.9   351    88.6          
      Other/Unknown                                      515         5.0                      21    5.2    63        5.3    20     5.1           
  Ethnicity                                                                                                                                      
      Hispanic                                           313         3.0                      12    2.9    0.111     41     3.5    12     3.0    0.919
      Not Hispanic                                       9354        90.7                     360   88.2   1047      88.1   351    88.6          
      Unknown                                            644         6.3                      36    8.8    100       8.4    33     8.3           
  Primary payer                                                                                                                                  
      Commercial                                         5568        54.0                     229   56.1   0.149     650    54.7   218    55.1   0.356
      Medicaid                                           203         2.0                      5     1.2    23        1.9    5      1.3           
      Medicare                                           3535        34.3                     146   35.8   415       34.9   145    36.6          
      Other Payor Type                                   176         1.7                      4     1.0    10        0.8    4      1.0           
      Uninsured                                          116         1.1                      0     0.0    13        1.1    0      0.0           
      Unknown                                            713         6.9                      24    5.9    77        6.5    24     6.1           
  Geographic area                                                                                                                                
      Midwest                                            4354        42.2                     120   29.4   \<0.001   359    30.2   120    30.3   0.999
      Northeast                                          813         7.9                      52    12.8   143       12.0   48     12.1          
      Other/Unknown                                      209         2.0                      4     1.0    14        1.2    4      1.0           
      South                                              3729        36.2                     211   51.7   608       51.2   203    51.3          
      West                                               1206        11.7                     21    5.2    64        5.4    21     5.3           
  Percent college educated                                                                                                                       
      14 to 18%                                          2375        23.0                     146   35.8   \<0.001   443    37.3   139    35.1   0.903
      19 to 28%                                          4625        44.9                     133   32.6   378       31.8   132    33.3          
      \< 14%                                             185         1.8                      3     0.7    6         0.5    3      0.8           
      \>28%                                              2915        28.3                     122   29.9   347       29.2   118    29.8          
      Unknown                                            211         2.1                      4     1.0    14        1.2    4      1.0           
  Average household income                                                                                                                       
      0K to 35K                                          2250        21.8                     107   26.2   0.005     288    24.2   104    26.3   0.899
      36K to 41K                                         3022        29.3                     139   34.1   396       33.3   133    33.6          
      42K to 51K                                         2241        21.7                     79    19.4   237       20.0   78     19.7          
      52K+                                               2587        25.1                     79    19.4   253       21.3   77     19.4          
      Unknown                                            211         2.1                      4     1.0    14        1.2    4      1.0           
  Year and quarter of index date                                                                                                                 
      01OCT2012                                          3685        35.7                     14    3.4    \<0.001   42     3.5    14     3.5    0.995
      01JAN2013                                          1269        12.3                     20    4.9    54        4.6    20     5.1           
      01APR2013                                          798         7.7                      41    10.1   133       11.2   40     10.1          
      01JUL2013                                          753         7.3                      50    12.3   140       11.8   49     12.4          
      01OCT2013                                          685         6.6                      58    14.2   169       14.2   53     13.4          
      01JAN2014                                          1135        11.0                     92    22.6   284       23.9   91     23.0          
      01APR2014                                          750         7.3                      59    14.5   154       13.0   57     14.4          
      01JUL2014                                          622         6.0                      32    7.8    96        8.1    32     8.1           
      01OCT2014                                          614         6.0                      42    10.3   116       9.8    40     10.1          
  Falsification outcomes (post-index)                                                                                                            
      Shingles                                           223         2.2                      7     1.7    0.541     29     2.4    7      1.8    0.436
     Hepatitis C                                         47          0.5                      2     0.5    0.920     6      0.5    2      0.5    1.000
      Hepatitis C or Shingles                            269         2.6                      9     2.2    0.616     35     3.0    9      2.3    0.480
      CAP                                                1032        10.0                     32    7.8    0.151     106    8.9    31     7.8    0.502
  Body mass index category                                                                                                                       
      18.5--24.9                                         2310        22.4                     91    22.3   \<0.001   246    20.7   89     22.5   0.961
      25.0--29.9                                         2994        29.0                     151   37.0   442       37.2   143    36.1          
      \<18.5                                             136         1.3                      6     1.5    17        1.4    6      1.5           
      \> = 30.0                                          4229        41.0                     152   37.3   460       38.7   150    37.9          
      Unknown                                            642         6.2                      8     2.0    23        1.9    8      2.0           
  Earliest baseline systolic blood pressure available                                                                                            
      12+ months                                         217         2.1                      8     2.0    0.133     30     2.5    8      2.0    0.899
      3 to \<6 months                                    1507        14.6                     47    11.5   144       12.1   45     11.4          
      6 to \<9 months                                    682         6.6                      22    5.4    68        5.7    21     5.3           
      9 to \<12 months                                   414         4.0                      11    2.7    40        3.4    11     2.8           
      \<3 months                                         7491        72.7                     320   78.4   906       76.3   311    78.5          
  Earliest baseline diastolic blood pressure available                                                                                           
      12+ months                                         217         2.1                      8     2.0    0.132     30     2.5    8      2.0    0.899
      3 to \<6 months                                    1507        14.6                     47    11.5   144       12.1   45     11.4          
      6 to \<9 months                                    683         6.6                      22    5.4    68        5.7    21     5.3           
      9 to \<12 months                                   414         4.0                      11    2.7    40        3.4    11     2.8           
      \<3 months                                         7490        72.6                     320   78.4   906       76.3   311    78.5          
  JNC7                                                                                                                                           
      Other                                              60          0.6                      3     0.7    0.963     10     0.8    3      0.8    0.986
      SBP 120--139 or DBP 80--89 mmHg                    5910        57.3                     239   58.6   679       57.2   230    58.1          
      SBP 140--159 or DBP 90--99 mmHg                    1374        13.3                     56    13.7   173       14.6   56     14.1          
      SBP \>160 or DBP \>100 mmHg                        220         2.1                      7     1.7    26        2.2    7      1.8           
      SBP\<120 and DBP\<80 mmHg                          2745        26.6                     103   25.3   300       25.3   100    25.3          
      Unknown                                            2           0.0                      0     0.0                                          
  Baseline cholesterol available                                                                                                                 
      HDL                                                6995        67.8                     255   62.5    0.024    736    62.0   251    63.4   
      LDL                                                7033        68.2                     255   62.5   0.015     736    62.0   251    63.4   0.611
  Cardiovascular events prior to index date                                                                                                      
      MACE event \<3 months prior                        232         2.3                      13    3.2    0.215     35     3.0    13     3.3    0.735
      MACE event 3--12 months prior                      403         3.9                      18    4.4     0.608    43     3.6    18     4.6    0.407
      MACE event \>12 months prior                       816         7.9                      37    9.1     0.398    111    9.3    36     9.1    0.881
      Non MACE event \<3 months prior                    149         1.5                      10    2.5    0.099     17     1.4    10     2.5    0.145
      Non MACE event 3--12 months prior                  287         2.8                      9     2.2    0.485     28     2.4    9      2.3    0.924
      Non MACE event \>12 months prior                   587         5.7                      28    6.9    0.319     77     6.5    26     6.6    0.953
      Any MACE event \<3 months prior                    307         3.0                      19    4.7    0.053     43     3.6    19     4.8    0.295
      Any MACE event 3--12 months prior                  531         5.2                      22    5.4    0.828     53     4.5    22     5.6    0.375
      Any MACE event \>12 months prior                   1004        9.7                      48    11.8   0.177     128    10.8   46     11.6   0.643
  Comorbidities                                                                                                                                  
      Congestive heart failure                           1096        10.6                     51    12.5   0.231     144    12.1   46     11.6   0.789
      Valvular disease                                   1641        15.9                     95    23.3   \<0.001   262    22.1   87     22.0   0.972
      Pulmonary circulation disease                      561         5.4                      26    6.4    0.417     70     5.9    23     5.8    0.951
      Peripheral vascular disease                        1876        18.2                     102   25.0   \<0.001   257    21.6   91     23.0   0.575
      Hypertension                                       6571        63.7                     268   65.7   0.420     754    63.5   256    64.7   0.673
      Paralysis                                          508         4.9                      19    4.7    0.805     56     4.7    19     4.8    0.946
      Other neurological disorders                       2173        21.1                     109   26.7   0.006     279    23.5   100    25.3   0.475
      Chronic pulmonary disease                          2736        26.5                     124   30.4   0.084     325    27.4   120    30.3   0.259
      Diabetes w/o chronic complications                 2856        27.7                     144   35.3   0.001     401    33.8   135    34.1   0.902
      Diabetes w/ chronic complications                  1271        12.3                     60    14.7   0.153     167    14.1   57     14.4   0.868
      Hypothyroidism                                     2346        22.8                     115   28.2   0.011     311    26.2   109    27.5   0.599
      Renal failure                                      1275        12.4                     43    10.5   0.271     123    10.4   43     10.9   0.776
      Liver disease                                      517         5.0                      21    5.2    0.904     61     5.1    21     5.3    0.896
      Peptic ulcer Disease x bleeding                    32          0.3                      3     0.7    0.140     2      0.2    2      0.5    0.248
      Acquired immune deficiency syndrome                25          0.2                      0     0.0    0.319     2      0.2    0      0.0    0.414
      Lymphoma                                           123         1.2                      12    2.9    0.002     30     2.5    11     2.8    0.784
      Metastatic cancer                                  280         2.7                      9     2.2    0.533     24     2.0    9      2.3    0.761
      Solid tumor w/out metastasis                       1710        16.6                     76    18.6   0.277     203    17.1   73     18.4   0.541
      Rheumatoid arthritis/collagen vas                  1037        10.1                     52    12.8   0.078     130    10.9   48     12.1   0.520
      Coagulopathy                                       517         5.0                      21    5.2    0.904     67     5.6    19     4.8    0.522
      Obesity                                            1880        18.2                     64    15.7   0.190     207    17.4   63     15.9   0.487
      Weight loss                                        869         8.4                      33    8.1    0.809     83     7.0    33     8.3    0.373
      Fluid and electrolyte disorders                    2047        19.9                     86    21.1   0.543     226    19.0   79     20.0   0.686
      Chronic blood loss anemia                          279         2.7                      15    3.7    0.239     29     2.4    13     3.3    0.367
      Deficiency anemia                                  2651        25.7                     123   30.2   0.045     306    25.8   116    29.3   0.168
      Alcohol abuse                                      199         1.9                      7     1.7    0.757     18     1.5    6      1.5    1
      Drug abuse                                         236         2.3                      12    2.9    0.390     25     2.1    12     3.0    0.291
      Psychoses                                          1597        15.5                     65    15.9   0.808     169    14.2   64     16.2   0.346
      Depression                                         2543        24.7                     101   24.8   0.966     274    23.1   99     25.0   0.432
  Index medications                                                                                                                              
      History of prior antimuscarinic use                4327        42.0                     67    16.4   \<0.001   229    19.3   67     16.9   0.297
      Antihistamine Drugs                                39          0.4                      2     0.5    0.719     4      0.3    2      0.5    0.637
      Anti-infective Agents                              851         8.3                      11    2.7    \<0.001   34     2.9    11     2.8    0.930
      Antineoplastic Agents                              52          0.5                      0     0.0    0.151     8      0.7    0      0.0    0.102
      Autonomic Drugs                                    629         6.1                      9     2.2    0.001     22     1.9    9      2.3    0.601
      Antithrombotic Agents                              242         2.4                      4     1.0    0.071     17     1.4    4      1.0    0.526
      Hematopoietic Agents                               1           0.0                      0     0.0    0.842                                 
          Hemorrheologic Agents                          5           0.1                      0     0.0    0.656     2      0.2    0      0.0    0.414
      Antihemorrhagic Agents                             1           0.0                      0     0.0    0.842                                 
      Antiarrhythmic Agents                              19          0.2                      0     0.0    0.386     3      0.3    0      0.0    0.317
      Cardiotonic Agents                                 33          0.3                      0     0      0.252     2      0.2    0      0.0    0.414
      Cardiac Drugs, Miscellaneous                       6           0.1                      0     0      0.626     1      0.1    0      0.0    0.564
      Antilipemic Agents                                 926         9.0                      25    6.13   0.047     75     6.3    24     6.1    0.857
      Hypotensive Agents                                 45          0.4                      1     0.25   0.562     7      0.6    1      0.3    0.413
      Vasodilating Agents                                80          0.8                      3     0.74   0.927     13     1.1    3      0.8    0.562
      Alpha-Adrenergic Blocking Agents                   48          0.5                      3     0.74   0.437     7      0.6    2      0.5    0.847
      Beta-Adrenergic Blocking Agents                    517         5.0                      13    3.19   0.095     41     3.5    13     3.3    0.873
      Calcium-Channel Blocking Agents                    416         4.0                      12    2.94   0.269     33     2.8    12     3.0    0.793
      Renin-Angiotensin-Aldosterone System Inhibitors    813         7.9                      24    5.88   0.139     62     5.2    23     5.8    0.652
      Diuretics                                          434         4.2                      11    2.7    0.133     38     3.2    11     2.8    0.675

CAP = Community-acquired pneumonia; DBP = Diastolic blood pressure; HDL = High-density lipoprotein; JNC-7 = Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; LDL = Low-density lipoprotein; MACE = Major adverse cardiac event; SBP = Systolic blood pressure

The results of the falsification analysis on the propensity-matched population are shown in [Fig 3](#pone.0205640.g003){ref-type="fig"}. Due to the relative infrequency of shingles and hepatitis C virus, they were combined *post hoc* into a composite endpoint. There was no statistical evidence of a spurious association between any of the falsification endpoints and mirabegron or antimuscarinic treatment (all 95% confidence intervals span 1.0). However, the confidence intervals were wide, particularly for hepatitis C (point estimate 1.5, 95% confidence interval 0.27--8.2). Thus, due in part to the low sample size contributing to a lack of power, the presence of residual bias (as evidenced by an odds ratio different than 1.0) in the propensity-matched dataset could not be ruled out.

![Results of falsification analysis.](pone.0205640.g003){#pone.0205640.g003}

Discussion {#sec008}
==========

This study aimed to characterize the cardiovascular risk profile of untreated, mirabegron-treated, and antimuscarinic-treated OAB patients, using an integrated claims/EHR dataset. An incremental analytical approach was implemented to ensure rigor and accuracy within the constraints of observational data. In a retrospective cohort of individuals with OAB, mirabegron patients were found to be older, with more comorbidities and more prior cardiovascular events relative to antimuscarinic patients. Mirabegron is typically prescribed as a second-line agent to antimuscarinics, due to either inadequate response or poor tolerability of antimuscarinics, or due to formulary rules e.g. stepped therapy conditions. As such, unadjusted comparisons of treatment effectiveness or safety between mirabegron and antimuscarinics based on these data may be biased by differences in the distribution of baseline risk factors between treatment cohorts. Indeed, despite what appeared to be adequate propensity score matching, when residual bias was assessed through falsification analyses, the resulting confidence intervals were sufficiently wide that associations with falsification outcomes (as evidenced by wide intervals) could not be ruled out. The small sample size ultimately eligible for study inclusion--due to the significant attrition caused by lack of overlap of subjects between the claims and EHR datasets, and application of the relatively limited exclusion criteria--contributed to limited power and to confidence interval width, preventing a definitive interpretation of results and conclusions.

Bias assessment for the cardiovascular outcomes study, the initiation of which would be based on the results of the feasibility assessment, was defined with two pre-specified stopping rules with respect to data quality and study feasibility. The first stopping rule instructed no further analyses if there was evidence of sufficiently implausible data (i.e. clinical data values that were physically impossible and assumed to be data entry errors, assessed on a case-by-case basis) or frequency of missing data as assessed by the initial data quality assessment. The second stopping rule was a determination of feasibility after propensity-score matching, based on achievement of covariate balance, available sample size, and results of falsification analysis. No assessment of primary or secondary endpoints for the cardiovascular outcomes study was conducted prior to confirming the results of the stopping rules, to ensure that outcome values had no influence on the decision to continue the study. In accordance with the second analytic stopping rule, this, together with the potential for residual bias identified by the falsification analyses, led to the conclusion that there was insufficient evidence to rule out bias in the available data, and that the cardiovascular outcomes study could not be robustly carried out at this time. Future real-world administrative database studies assessing clinical outcomes across OAB treatments will require careful accounting for the clinical differences inherent in comparing populations receiving a second-line agent to a first-line agent beyond that achieved by standard methods such as propensity scoring; data sources with larger sample sizes available may mitigate the limitations caused by low power observed here. By planning the cardiovascular outcomes study with pre-specified stopping rules, primary and secondary endpoint results data were not analyzed in any way prior to making stopping decisions for the study. This ensured information about results could not influence the decision of whether to proceed with further analyses.

Electronic health records have been used previously to assess blood pressure outcomes,\[[@pone.0205640.ref014], [@pone.0205640.ref025]--[@pone.0205640.ref029]\] and are acknowledged by the US Food and Drug Administration for use in prospective clinical investigations of medications.\[[@pone.0205640.ref030]\] Integrated claims and EHR datasets can also be valuable research tools to assess clinical and pharmacoepidemiologic questions due to large sample sizes, long follow-up durations, and the inclusion of patients with complex medical needs who would not be likely candidates for clinical trial participation and cannot feasibly be assessed within an RCT framework. Indeed, in the search for robust real-world data, claims and EHR data sources are often cited as a powerful source of evidence, and the availability of large sample sizes is a frequently-noted feature.\[[@pone.0205640.ref031]\] That said, as reported here, rigorously identifying the study cohort and appropriately controlling for potential biases may impact the feasibility of using these data for complex clinical and pharmacoepidemiologic questions. Indeed, this study highlights that even for a relatively common condition such as OAB (with a study requirement for recorded claims data), sample size remained a limiting factor within a large administrative dataset.

With respect to the potential for selection bias in observational data sources, supplementing propensity scores with statistical techniques such as falsification analysis (also referred to as negative control analysis),\[[@pone.0205640.ref032]\] can help to assess whether an unbiased comparison is feasible with the available data, and can provide confidence in the interpretation of results. However, identification of appropriate endpoints can be challenging; in the case of OAB, the potential for an association between exposure and cardiovascular risk factors limits the availability of possible falsification endpoints with no plausible chance of association to treatment group. As a result, although expected frequency was a criterion used when selecting candidate falsification endpoints, the sample size was inadequate to conduct a conclusive falsification analysis. This highlights the importance of a large sample size, not only for attaining sufficient statistical power required for primary analyses, but also for bias assessment techniques. The methods described here may be used as a framework for other investigators who are considering real-world data to investigate other clinical and pharmacoepidemiologic research questions.

While data quality checks did not identify any notable concerns regarding data quality or conclusive evidence of residual bias, the magnitude of variability in falsification analysis results could not conclusively rule out the potential for residual bias in the sample after statistical adjustment. The most important concern with the data, eventually leading to the decision to not proceed with analysis, was the small sample of eligible mirabegron patients, including the attrition induced by individuals who were prescribed therapy but did not fill their prescription. In particular, the low number of patients relative to available mirabegron clinical trial populations, for which a similar length of follow-up is available for samples of 400--800 patients,\[[@pone.0205640.ref033]--[@pone.0205640.ref036]\] did not justify the potential for additional biases associated with observational research. It was notable that, of patients identified as receiving mirabegron or an antimuscarinic in EHR data, more than half were excluded for not having corresponding claims records. This may reflect problems with primary adherence to OAB medications, with patients choosing not to access prescribed medications; however, this feature of the data also highlights a potential limitation with linked EHR and claims data generally, in that dispensed prescriptions may not be reflected in claims data due to plan discontinuation and/or other changes in coverage.

While the relatively small sample size of mirabegron patients coupled with the low prevalence of the falsification endpoints of interest did not directly lead to the decision to stop the cardiovascular outcomes study, it may have contributed to the interpretation that falsification endpoints were unable to definitively rule out residual bias, as determined by the wide confidence intervals rather than point estimates. As such, a similar analysis in a larger sample may have been found sufficient to warrant continuation with the cardiovascular outcomes study. A recently-conducted US Food and Drug Administration mini-sentinel study acknowledged similar limitations; they did not find a difference in risk of acute myocardial infarction or stroke between new users of mirabegron vs. oxybutynin, while noting limitations due to available follow-up time and sparseness of outcomes.\[[@pone.0205640.ref037]\]

While long-term follow up of the real-world safety and effectiveness profiles of mirabegron and antimuscarinics warrants further consideration, the limited scope of available data is challenging for comparative analyses. The methodology presented here describes a framework for any treatment comparative analysis using real world observational data where treatment attributes may be at risk of residual confounding bias.

Appendix A: Sample size calculation {#sec009}
===================================

Using a repeated measures analysis of variance (RM-ANOVA) carried out over 4 time points (0, 3, 6, and 12 months), sample sizes needed to detect clinically relevant differences in SBP/DBP were calculated on the basis of a global hypothesis that tests for equality between the two treatment groups at every time point.\[[@pone.0205640.ref036]\] This global test is appropriate whenever there are a wide variety of hypotheses of interest, including, for example, treatment differences at one or more time points, or comparisons between the change scores from one set of time points to another, etc. In this test, protection against a Type I error is maintained at the prescribed alpha-level for all such comparisons.\[[@pone.0205640.ref038]\] To err on the conservative side, the Type I error for comparing mean change from baseline at 3, 6 and 12 months for the co-primary endpoints of change in systolic and diastolic blood pressures was initially set at 0.05/3 = 0.0167 so as to yield an overall Bonferroni-adjusted Type I error of 0.05. Power was set at 0.90. Under conservative assumptions regarding correlation\[[@pone.0205640.ref038]\] and assuming 1:1 matching of patients, sample size calculations showed that detecting a systolic blood pressure difference of 2.5 mmHg requires 1,117 individuals in each treatment group assuming a 14 mm Hg standard deviation, and 2,277 individuals in each treatment group assuming a 20 mm Hg standard deviation.\[[@pone.0205640.ref039]\] However, based on a lower than anticipated number of eligible mirabegron patients relative to antimuscarinic patients, revised sample size calculations were made based on a 3:1 matching of antimuscarinic to mirabegron patients with the Type I error set at 0.05. At power of 0.80, a sample of 500 mirabegron patients and 1500 antimuscarinic patients would be required to detect a systolic blood pressure difference of 2.5 mmHg assuming a 14 mmHg standard deviation. When based on a power of 0.90, the sample size increased to 645 mirabegron patients and 1935 antimuscarinic patients.
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